A narrative review of the literature: The role of biologics and JAK inhibitors in vitiligo.

Russell, Rhiannon; Daniel, Benjamin S

Russell, Rhiannon; Daniel, Benjamin S.

Afiliación

Russell R; Department of Dermatology, Liverpool Hospital, Sydney, Australia.
Daniel BS; Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia.

Australas J Dermatol ; 2024 Aug 01.

Article en En | MEDLINE | ID: mdl-39087440

ABSTRACT

ABSTRACT

Vitiligo is a chronic depigmenting disorder that significantly impacts the quality of life of patients. Though there have been significant advancements in targeted therapies in skin diseases such as psoriasis or eczema, the progress in the treatment of vitiligo has been slow, with minimal studies assessing the effect of biologics, though there has been recent evidence of the effectiveness of JAK inhibition. This paper reviews the published case reports and studies for the use of systemic targeted therapies including biologics and JAK inhibitors in vitiligo.

Palabras clave

JAK inhibitor; adalimumab; biologics; guselkumab; infliximab; ixekizumab; risankizumab; rituximab; secukinumab; tildrakizumab; ustekinumab; vitiligo

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Australas J Dermatol Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Australia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google